Regencor Inc. Email Format
Biotechnology ResearchCalifornia, United States2-10 Employees
Regencor Inc. is a privately held biotechnology research company focused on regenerative medicine for heart disease, based in San Carlos, California. Its work centers on developing therapies that promote controlled proliferation of heart muscle cells in the infarct zone, with the aim of restoring ventricular contractility, reducing scar tissue, and preventing progression to heart failure. The company is pursuing two sustained-release formulations of its therapeutic agent, a recombinant non-glycosylated variant of FSTL1, for delivery to acute myocardial infarction patients during revascularization and for administration to heart failure patients, targeting both immediate and ongoing treatment needs. Regencor operates within the cardiovascular biotechnology sector, seeking to address the morbidity and mortality associated with myocardial infarction and subsequent heart failure through regenerative approaches. The firm has publicly announced the addition of new scientific advisors in March 2023, reflecting ongoing development and external expertise supporting its program.